Clinical manifestations | Suggested treatment |
Congenital CMV (cCMV) infection | |
Approximately 90% of affected newborns are asymptomatic. Among newborns with symptomatic cCMV, clinical and laboratory findings can include:
| Asymptomatic infants do not require antiviral treatment. For infants with symptomatic cCMV, treatment consists of IV ganciclovir or oral valganciclovir.* |
Early postnatal CMV infection | |
Term infants – Most infants are asymptomatic. Clinical and laboratory findings are usually transient and can include:
Preterm VLBW infants – Infection can be severe and life-threatening.
| Most otherwise healthy term infants and asymptomatic preterm infants do not require antiviral treatment. For infants with severe manifestations of postnatal CMV infection, treatment consists of IV ganciclovir or oral valganciclovir.* |
CMV infection in immunocompetent children and adolescents | |
In most cases, the infection does not cause symptoms or causes nonspecific symptoms consistent with other childhood viral illnesses. Symptoms can include:
Laboratory abnormalities may include:
Unlike mononucleosis caused by EBV, the monospot test is negative in CMV mononucleosis. | Supportive care with hydration and fever control. Antiviral treatment is generally not indicated. |
Infection in immunocompromised children and adolescents | |
Infection can be severe and life-threatening. Clinical and laboratory findings can include:
| IV ganciclovir or oral valganciclovir.* |
CMV: cytomegalovirus; HIV: human immunodeficiency virus; IV: intravenous; NEC: necrotizing enterocolitis; VLBW: very low birth weight.
* Refer to UpToDate's topics on CMV infections in infants and children for additional details regarding antiviral therapy.